Company intelligence / Profile preview
Shanghai Haini Pharmaceutical Co., Ltd.
- Ownership
- Private
- Development stage
- Other
Overview
Shanghai Haini Pharmaceutical develops and manufactures pharmaceutical products with a focus on small molecule drugs and antibiotics. It has an active clinical pipeline including drugs targeting gastroesophageal reflux disease and neuralgia. The company also holds exclusive rights to manufacture, develop, and commercialize the antibiotic combination cefepime/enmetazobactam in Greater China through a licensing agreement with Allecra Therapeutics. Some programs have reached late-stage development or regulatory submission.[3][6]
- Therapeutic areas
- GastroenterologyNeurologyInfectious Diseases
- Modalities
- Small moleculesAntibiotics
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Shanghai Haini Pharmaceutical Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Haini Pharmaceutical Co., Ltd..